skip to content

Cookies on the EU website

We use cookies to give the best experience on our site. Continue without changing your settings, and you'll receive cookies, or change your cookie settings at any time.


EU Clinical Trials Directive: What to expect from the revised legislation

The European Parliament Information Office in the UK organised a specialist discussion on the future of the EU Clinical Trials Directive on Friday 22 February 2013.  

Leading the debate were:

- Glenis Willmott MEP, the appointed European Parliament's rapporteur on the dossier.  
- Stefano Soro, Head of Unit within the European Commission's Directorate-General Health and Consumers
- Dr Liz Philpots, Head of Research, Association of Medical Research Charities
- Prof. Michele de Luca, Principal Investigator in European Commission FP7-funded Stem Cell research consortium, OptiStem"
- Fiona Fox, (Moderator) Chief Executive, The Science Media Centre

The Clinical Trials Directive (2001/20/EC) has been controversial among researchers, industry and patients alike for its heavy regulatory requirements and lack of multinational harmonisation, among other issues. Following a recent European Commission proposal to cut red tape and restore European Union's competitiveness in clinical research, the issue has now been taken up by the European Parliament. This event gave stakeholders and specialist media a chance to find out the latest developments in the revision of the legislation and feed in their thoughts on the direction that the EU should take.

Date | Friday, 22 February 2013
Time | 10.30am for 11am - 12.30pm
Place| Europe House, 32 Smith Square, London SW1P 3EU

Glenis Willmott's Report on Clinical Trials Directive

Our event in the Press




EU Clinical Trials Directive: Footage